Enanta Pharmaceuticals. has been granted a patent for compounds that inhibit Apoptosis signal-regulating kinase 1 (ASK-1), targeting diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The patent includes methods for treating these conditions using the specified compounds. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12018017B2 outlines a method for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in subjects requiring intervention. The treatment involves administering a therapeutically effective amount of specific compounds, which are represented by various chemical formulas, including Formula (I) and its pharmaceutically acceptable salts or esters. The claims detail the structural variations of these compounds, allowing for a range of potential therapeutic agents to be utilized in the treatment process.
Further claims specify particular substituents (R1, R2, R3) and various compound structures (e.g., Formula (IVa-1), (IVb-1), (Va-1), (Vb-1), (VIa-1), and (VIb-1)) that can be employed in the method. The patent also encompasses a selection of compounds that may be used, emphasizing the versatility of the treatment approach. This comprehensive framework aims to provide effective therapeutic options for individuals suffering from NAFLD or NASH, addressing a significant health concern associated with metabolic disorders.
To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
